Education
About Us
Working with TipRanks
Follow Us
Incannex Healthcare Limited Sponsored ADR (IXHL)
NASDAQ:IXHL
RESEARCH TOOLSreports
IXHL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.08 - $3.55
Previous CloseN/A
Volume10.98K
Average Volume (3M)2.21M
Market Cap
$2.34M
Enterprise ValueN/A
Total Cash (Recent Filing)$2.10M
Total Debt (Recent Filing)$4.10M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Aug 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding27,546,753
10 Day Avg. Volume5,869,539
30 Day Avg. Volume2,214,202
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)2.42
Price to Sales (P/S)0.00
P/FCF Ratio-0.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Incannex Healthcare Limited Sponsored ADR News
PremiumMarket News
3 Penny Stocks to Watch Now, 5/15/25
PremiumCompany Announcements
Incannex Healthcare Reports Q3 2025 Financial Results
PremiumCompany Announcements
Incannex Completes Patient Dosing in Phase 2 Study
---
Options Prices
Currently, No data available
---
Ownership Overview
0.36% Insiders
0.12% Mutual Funds
0.69% Other Institutional Investors
97.58% Public Companies and
Individual Investors
IXHL FAQ
What was Incannex Healthcare Limited Sponsored ADR’s price range in the past 12 months?
Incannex Healthcare Limited Sponsored ADR lowest stock price was $0.08 and its highest was $3.55 in the past 12 months.
What is Incannex Healthcare Limited Sponsored ADR’s market cap?
Incannex Healthcare Limited Sponsored ADR’s market cap is $2.34M.
When is Incannex Healthcare Limited Sponsored ADR’s upcoming earnings report date?
Incannex Healthcare Limited Sponsored ADR’s upcoming earnings report date is Aug 27, 2025 which is in 104 days.
How were Incannex Healthcare Limited Sponsored ADR’s earnings last quarter?
Incannex Healthcare Limited Sponsored ADR released its earnings results on Feb 14, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.44 by $0.11.
Is Incannex Healthcare Limited Sponsored ADR overvalued?
According to Wall Street analysts Incannex Healthcare Limited Sponsored ADR’s price is currently Overvalued.
Does Incannex Healthcare Limited Sponsored ADR pay dividends?
Incannex Healthcare Limited Sponsored ADR does not currently pay dividends.
What is Incannex Healthcare Limited Sponsored ADR’s EPS estimate?
Incannex Healthcare Limited Sponsored ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Incannex Healthcare Limited Sponsored ADR have?
Incannex Healthcare Limited Sponsored ADR has 27,546,753 shares outstanding.
What happened to Incannex Healthcare Limited Sponsored ADR’s price movement after its last earnings report?
Incannex Healthcare Limited Sponsored ADR reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.44. Following the earnings report the stock price went down -1.111%.
Which hedge fund is a major shareholder of Incannex Healthcare Limited Sponsored ADR?
Currently, no hedge funds are holding shares in IXHL
---
Incannex Healthcare Limited Sponsored ADR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-96.75%
12-Months-Change
Fundamentals
Return on Equity
-240.02%
Trailing 12-Months
Asset Growth
-50.33%
Trailing 12-Months
Company Description
Incannex Healthcare Limited Sponsored ADR
Incannex Healthcare Limited Sponsored ADR (IXHL) is a healthcare company focused on the development and commercialization of medicinal cannabinoid and psychedelic pharmaceutical products. Operating primarily within the biotechnology and pharmaceuticals sectors, Incannex leverages cutting-edge research to address various medical conditions, including chronic pain, mental health disorders, and sleep apnea. The company is dedicated to developing innovative therapies through clinical trials and collaborations with leading research institutions.
---
Technical Analysis
---